These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38739858)

  • 1. LESS IS MORE: Reducing Injections and Optimizing Vision With Anti-VEGF Therapy for nAMD, DR, and DME.
    Retina; 2024 May; 44(5S):S1-S16. PubMed ID: 38739858
    [No Abstract]   [Full Text] [Related]  

  • 2. Patient Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
    Holekamp N; Gentile B; Giocanti-Aurégan A; García-Layana A; Peto T; Viola F; Kertes PJ; Mirt M; Kotecha A; Lambert J; Lewis HB; Chi GC
    Ophthalmic Res; 2024; 67(1):311-321. PubMed ID: 38679018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visual outcomes following anti-VEGF therapy in patients with DME.
    Panigrahi PK; Patro M
    Indian J Ophthalmol; 2024 Jul; 72(Suppl 4):S718. PubMed ID: 38953138
    [No Abstract]   [Full Text] [Related]  

  • 4. Individualized treat-and-extend regime for optimization of real-world vision outcome and improved patients' persistence.
    Volkmann I; Knoll K; Wiezorrek M; Greb O; Framme C
    BMC Ophthalmol; 2020 Mar; 20(1):122. PubMed ID: 32228517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema.
    Zehetner C; Kirchmair R; Huber S; Kralinger MT; Kieselbach GF
    Br J Ophthalmol; 2013 Apr; 97(4):454-9. PubMed ID: 23385630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
    Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
    Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
    Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
    Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial.
    Bressler NM; Beaulieu WT; Glassman AR; Blinder KJ; Bressler SB; Jampol LM; Melia M; Wells JA;
    JAMA Ophthalmol; 2018 Mar; 136(3):257-269. PubMed ID: 29392288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis.
    Low A; Faridi A; Bhavsar KV; Cockerham GC; Freeman M; Fu R; Paynter R; Kondo K; Kansagara D
    Br J Ophthalmol; 2019 Apr; 103(4):442-451. PubMed ID: 30409915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
    Krick TW; Bressler NM
    Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.
    Jampol LM; Glassman AR; Bressler NM; Wells JA; Ayala AR;
    JAMA Ophthalmol; 2016 Dec; 134(12):. PubMed ID: 27711918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice.
    Holekamp NM; Campbell J; Almony A; Ingraham H; Marks S; Chandwani H; Cole AL; Kiss S
    Am J Ophthalmol; 2018 Jul; 191():83-91. PubMed ID: 29684329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in cardiac troponin T level after intravitreal anti-vascular endothelial growth factor treatment: Prospective pilot study.
    Rebeiz AG; Mahfoud Z; Abdul Fattah M; Saad A; Safar A; Bashshur ZF
    Eur J Ophthalmol; 2020 May; 30(3):563-569. PubMed ID: 30813779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of anti-vascular endothelial growth factor on diabetic macular edema diagnosed with different patterns of optical coherence tomography: A network meta-analysis.
    Yao J; Huang W; Gao L; Liu Y; Zhang Q; He J; Zhang L
    PLoS One; 2024; 19(6):e0304283. PubMed ID: 38848379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of Response between Both Eyes to First- and Second-Line Anti-VEGF Therapy in Diabetic Macular Edema.
    Tiosano L; Ayalon A; Banin E; Averbukh E; Jaouni T; Chowers I
    Curr Eye Res; 2021 Apr; 46(4):539-545. PubMed ID: 32804540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
    Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
    JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effectiveness of Intravitreal Ranibizumab in Patients with Diabetic Macular Edema Who Have Failed to Respond to Intravitreal Bevacizumab.
    Ehrlich R; Dan I; Deitch I; Axer-Siegel R; Mimouni K
    Ophthalmologica; 2016; 235(3):133-6. PubMed ID: 26926483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema Treatment: Analysis From the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial.
    Ross EL; Hutton DW; Stein JD; Bressler NM; Jampol LM; Glassman AR;
    JAMA Ophthalmol; 2016 Aug; 134(8):888-96. PubMed ID: 27280850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changing Reimbursement Criteria on Anti-VEGF Treatment Patterns Among Wet Age-Related Macular Degeneration and Diabetic Macular Edema Patients: An Interrupted Time Series Analysis.
    Huang YW; Meng LC; Shen LJ; Huang CF; Chen LK; Hsiao FY
    Int J Health Policy Manag; 2024; 13():8210. PubMed ID: 39099486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.